Moderna, Merck Cancer Vaccine-Keytruda Combo Gets Win at Three-Year Mark

A combination of Merck’s blockbuster cancer drug Keytruda and an mRNA vaccine from Moderna has demonstrated positive results at the three-year stage in a Phase IIb study of patients with resected high-risk melanoma following complete resection.